



ITW

Approved for use through 07/31/2008. OMB 0051-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Project 0955, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/537,052 (Conf. #8397)
Filing Date	2 June 2005
First Named Inventor	Allan SHEPARD et al.
Art Unit	1614
Examiner Name	
Attorney Docket Number	2335 US F

### ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  corresponding PCT/US03/040511 Search Report [2 pp] and Return Card.
<input type="checkbox"/> Remarks _____		

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

First Name	Alcon Research, Ltd.		
Signature	<i>Teresa J. Schultz</i>		
Printed name	Teresa J. Schultz		
Date	11 October 2005	Reg. No.	40,526

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature	<i>Barbara McKenzie</i>		
Typed or printed name	Barbara McKenzie	Date	11 October 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.H./



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: Allan SHEPARD et al.

Serial No: 10/537,052 (Conf. #8397)

Filed: 2 June 2005

Examiner:

Group Art Unit: 1614

FOR: USE OF CATHEPSIN K INHIBITORS FOR THE TREATMENT OF GLAUCOMA

**INFORMATION DISCLOSURE STATEMENT PURSUANT  
TO 37 C.F.R. 1.56, 1.97, AND 1.98**Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants submit the patents, articles, and other information referenced in the specification as filed. The references are listed on the attached PTO Form 1449. Applicants are submitting copies of the foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2), copies of the U.S. patents are not enclosed.

A copy of the International Search Report issued in the PCT application, of which the present application is a 35 U.S.C. §371 application, is also included for the Examiner's convenience.

Applicants request that the listed patents, articles, and other information be considered during prosecution of this application and that they appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

11 October 2005  
DateBy: Teresa J. Schultz  
Teresa J. Schultz  
Registration No. 40,256  
(817) 551-4231Address for Correspondence:  
Alcon Research, Ltd.  
Attn: Teresa J. Schultz  
6201 S. Freeway, Mail Code Q-148  
Fort Worth, TX 76134-2099  
Attorney Docket No.: 2335 US F

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.H./



Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
to a collection of information unless it contains a valid OMB control number.

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/537,052 (Conf #8397)
Filing Date	2 June 2005
First Named Inventor	Allan SHEPARD
Art Unit	1614
Examiner Name	
Attorney Docket Number	2335 US F

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	/Gigi Huang/	Date Considered	11/22/2008
-----------------------	--------------	--------------------	------------

\* Examine initial. If reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* Applicant's unique citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language translation is attached.

Transaction is adjudicated.  
 Information is required by CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is a life (and by the USPTO) for a specific application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.H./

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Application Number</b>	10/537,052 (Conf. #8397)
		<b>Filing Date</b>	2 June 2005
		<b>First Named Inventor</b>	Allan SHEPARD
		<b>Art Unit</b>	1614
		<b>Examiner Name</b>	
<b>Sheet</b>	2	of	6
		<b>Attorney Docket Number</b>	2335 US F

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	B1	ALTMANN et al., "Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors," J. MED. CHEM. 45:2352-2354 (2002)	
	B2	BILLINGTON et al., "The slow-binding inhibition of cathepsin K by its propeptide," BIOCHEM. BIOPHYS. RES. COMMUN. 276:924-929 (2000)	
	B3	BOSSARD et al., "Mechanism of inhibition of cathepsin K by potent, selective 1,5-diacylcarbohydrazides: a new class of mechanism-based inhibitors of thiol proteases," BIOCHEMISTRY 38:15893-15902 (1999)	
	B4	BRÖMME et al., "Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L," BIOCHEM. J. 315:85-89 (1996)	
	B5	CLARK et al., "Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells," IOVS 35:281-294 (1994)	
	B6	CLAVEAU et al., Biochemical and Biophysical Research Communications 281:551-557 (2001)	
	B7	DICKERSON et al., "The effect of dexamethasone on integrin and laminin expression in cultured human trabecular meshwork cells," EXP EYE RES 66:731-738 (1998)	
	B8	FALGUEYRET et al., "Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L," J. MED. CHEM. 44:94-104 (2001)	
	B9	FENWICK et al., "Solid-phase synthesis of cyclic alkoxyketones; inhibitors of the cysteine protease cathepsin K," BIOORG. MED. CHEM. LETT. 11:195-198 (2001a)	
	B10	FENWICK et al., "Diastereoselective synthesis, activity and chiral stability of cyclic alkoxyketone inhibitors of cathepsin K," BIOORG. MED. CHEM. LETT. 11:199-202 (2001b)	

<b>Examiner Signature</b>	/Gigi Huang/	<b>Date Considered</b>	11/22/2008
---------------------------	--------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.H./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Application Number</b>	10/537,052 (Conf. #8397)
		<b>Filing Date</b>	2 June 2005
		<b>First Named Inventor</b>	Allan SHEPARD
		<b>Art Unit</b>	1614
		<b>Examiner Name</b>	
<b>Sheet</b>	3	of	6
		<b>Attorney Docket Number</b>	2335 US F

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	HAECKEL et al., Developmental Dynamics 216:89-95 (1999)	
	C2	KAMOLMATYAKUL, S., Chen, W., Li, Y.P., "Interferon- $\alpha$ down-regulates gene expression of cathepsin K in osteoclasts and inhibits osteoclast formation," J. DENT. RES. 80:351-355 (2001)	
	C3	KATUNUMA et al., "Study of the functional share of lysosomal cathepsins by the development of specific inhibitors," ADV. ENZYME REGUL. 39:247-260 (1999)	
	C4	KATUNUMA et al., "Structure-based development of pyridoxal propionate derivatives as specific inhibitors of cathepsin K in vitro and in vivo," BIOCHEM. BIOPHYS. RES. COMMUN. 267:850-854 (2000)	
	C5	KIVIRANTA et al., Journal of Bone And Mineral Research 16:1444-1452 (2001)	
	C6	LALONDE et al., "Use of papain as a model for the structure-based design of cathepsin K inhibitors: crystal structures of two papain-inhibitor complexes demonstrate binding to S'-subsites," J. MED. CHEM. 41:4567-4576 (1998)	
	C7	LARK et al., "A potent small molecule, nonpeptide inhibitor of Cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat," BONE 30(5):745-753 (2002)	
	C8	LEUNG-TOUNG et al., "Thiol-dependent enzymes and their inhibitors: a review", CURR MED CHEM 9:979-1002 (2002)	
	C9	MARQUIS et al., "Potent dipeptidylketone inhibitors of the cysteine protease cathepsin K," BIOORG. MED. CHEM. 7:581-588 (1999)	
	C10	MARQUIS et al., "Azebanone-based inhibitors of human and rat cathepsin K," J. MED. CHEM. 44:1380-1395 (2001a)	

<b>Examiner Signature</b>	/Gigi Huang/	<b>Date Considered</b>	11/22/2008
-------------------------------	--------------	----------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.H./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Application Number</b>	10/537,052 (Conf. #8397)
		<b>Filing Date</b>	2 June 2005
		<b>First Named Inventor</b>	Allan SHEPARD
		<b>Art Unit</b>	1614
		<b>Examiner Name</b>	
<b>Sheet</b>	4	of	6
		<b>Attorney Docket Number</b>	2335 US F

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	D1	MARQUIS et al., "Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K," J. MED. CHEM. 41:3563-3567 (1998)	
	D2	MARQUIS et al., "Cyclic ketone inhibitors of the cysteine protease cathepsin K," J. MED. CHEM. 44:725-736 (2001b)	
	D3	MATSUMOTO et al., "Structural basis of inhibition of cysteine proteases by E-64 and its derivatives," BIOPOLYMERS 51:99-107 (1999)	
	D4	MCGRATH, M.E., Klaus, J.L., Barnes, M.G., Bromme, D., "Crystal structure of human cathepsin K complexed with a potent inhibitor," NAT. STRUCT. BIOL. 4:105-109 (1997)	
	D5	MOTYCKOVA et al., PNAS 98:5798-5803 (2001)	
	D6	ORTEGO et al., "Gene expression of proteases and protease inhibitors in the human ciliary epithelium and ODM-2 cells," EXP. EYE RES. 65:289-299 (1997)	
	D7	PATIL et al., "A new dimeric dihydrochalcone and a new prenylated flavone from the bud covers of <i>Artocarpus altilis</i> : potent inhibitors of cathepsin K," J NAT PROD 65:624-627 (2002a)	
	D8	PATIL et al., "Haplocleridine, a novel tryptamine-derived alkaloid from a sponge of the order haploclerida: an inhibitor of cathepsin K," J NAT PROD 65:628-629 (2002b)	
	D9	PERCIVAL et al., "Inhibition of cathepsin K by nitric oxide donors: evidence for the formation of mixed disulfides and a sulfenic acid," BIOCHEMISTRY 38:13574-13583 (1999)	
	D10	SAFTIG, et al., Proc. Natl. Acad. Sci. 95:13453-13458 (1998)	

<b>Examiner Signature</b>	/Gigi Huang/	<b>Date Considered</b>	11/22/2008
---------------------------	--------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	10/537,052 (Conf. #8397)
Filing Date	2 June 2005
First Named Inventor	Allan SHEPARD
Art Unit	1614
Examiner Name	
Attorney Docket Number	2335 US F

Sheet	5	of	6
-------	---	----	---

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	E1	SCHICK et al., "Cross-Class Inhibition of the Cysteine Proteinases Cathepsins K, L, and S by the Serpin Squamous Cell Carcinoma Antigen 1: A Kinetic Analysis", BIOCHEMISTRY 37:5258-5266 (1998)	
	E2	SHEPARD et al., "Delayed Secondary Glucocorticoid Responsiveness of MYOC in Human Trabecular Meshwork Cells", IOVS 42:3173-3181 (2001)	
	E3	SMITH et al., "Discovery and parallel synthesis of a new class of cathepsin K inhibitors", BIOORG MED CHEM LETT 11:2951-2954 (2001)	
	E4	STEELY et al., "The effects of dexamethasone on fibronectin expression in cultured human trabecular meshwork cells", IOVS 33:2242-2250 (1992)	
	E5	STROUP et al., "Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate", J BONE MINER RES 16(10):1739-1746 (2001)	
	E6	THOMPSON et al., "Design of potent and selective human cathepsin K inhibitors that span the active site," PROC. NATL. ACAD. SCI. U.S.A. 94:14249-14254 (1997)	
	E7	THOMPSON et al., "Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic," J. MED. CHEM. 41:3923-3927 (1998)	
	E8	THOMPSON et al., "Structure-based design of non-peptide, carbonylhydrazide-based cathepsin K inhibitors," BIOORG. MED. CHEM. 7:599-605 (1999)	
	E9	TURK, B., Turk, V., Turk, D., "Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors," BIOL. BHEM. 378:141-150 (1997)	
	E10	VOTTA et al., "Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo," J. BONE MINER. RES. 12:1396-1406 (1997)	

Examiner Signature	/Gigi Huang/	Date Considered	11/22/2008
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.H./

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	10/537,052 (Conf. #8397)
Filing Date	2 June 2005
First Named Inventor	Allan SHEPARD
Art Unit	1614
Examiner Name	
Attorney Docket Number	2335 US F

Sheet 6 of 6

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	F1	WANG et al., "Optimal procedure for extracting RNA from human ocular tissues and expression profiling of the congenital glaucoma gene FOXC1 using quantitative RT-PCR," MOL VIS 7:89-94 (2001)	
	F2	WILSON et al., "Dexamethasone induced ultrastructural changes in cultured human trabecular meshwork cells," CURR EYE RES 12:763 (1993)	
	F3	YAMASHITA et al., "Solid-phase synthesis of a combinatorial array of 1,3-bis(acylamino)-2-butanones, inhibitors of the cysteine proteases cathepsins K and L," J. COMB. CHEM. 1:207-215 (1999)	
	F4	YAMASHITA and DODDS, "Cathepsin K and the design of inhibitors of cathepsin K," CURR. PHARM. DES. 6:1-24 (2000)	
	F5	ZHAO, B., Janson, C.A., Amegadzie, B.Y., D'Alessio, K., Grillin, C., Hanning, C.R., Jones, C., Kurdyla, J., McQueney, M., Qiu, X., "Crystal structure of human osteoclast cathepsin K complex with E-64," NAT. STRUCT. BIOL. 4:109-111 (1997)	
	F6	International Search Report of a related PCT Application No. PCT/US2003/040511, mailed June 2, 2004	

Examiner Signature	/Gigi Huang/	Date Considered	11/22/2008
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.H./